The announcement is likely to be one of the last major strategic moves undertaken by J&J chief executive Alex Gorsky, who will hand over the reins to CEO-elect Joaquin Duato on 1 January.

Duato isn’t the first Johnson & Johnson CEO to deliver poor stock performance. Former CEO Alex Gorsky served as CEO from April 2012 to December 2022. In the nearly 10 years in the top role ...

Medical devices is the only J&J business to report directly to CEO Alex Gorsky. Subscribe to The Broadsheet, our newsletter on the world's most powerful women. Home ...

Duato isn’t the first Johnson & Johnson CEO to deliver poor stock performance. Former CEO Alex Gorsky served as CEO from April 2012 to December 2022. In the nearly 10 years in the top role ...